Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.

Billan S, Kaidar-Person O, Atrash F, Doweck I, Haim N, Kuten A, Ronen O.

Isr Med Assoc J. 2013 May;15(5):231-5.

2.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. Epub 2015 Oct 22.

PMID:
26675064
3.

Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.

Huang CE, Lu CH, Chen PT, Chan CH, Chen WC, Wang WH, Wu JY, Kuan FC, Lee KD, Chen CC.

J Clin Pharm Ther. 2012 Jun;37(3):342-7. doi: 10.1111/j.1365-2710.2011.01306.x. Epub 2011 Sep 26.

PMID:
21950487
4.

TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.

Strojan P, Grašič Kuhar C, Žumer B, Kadivec M, Karner K, Fajdiga I, Jančar B, Gale N, Poljak M, Kocjan BJ, Zakotnik B.

Head Neck. 2014 Nov;36(11):1555-61. doi: 10.1002/hed.23506. Epub 2013 Dec 18.

PMID:
24123552
5.

Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.

Prestwich RJ, Öksüz DÇ, Dyker K, Coyle C, Şen M.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e237-43. doi: 10.1016/j.ijrobp.2011.03.043. Epub 2011 May 27.

PMID:
21620580
7.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group.

N Engl J Med. 2007 Oct 25;357(17):1695-704.

8.

Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.

Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I.

Oral Oncol. 2006 Aug;42(7):675-84. Epub 2006 May 30.

PMID:
16731029
9.

[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].

Chilimoniuk M, Olszewska E, Maksimowicz T.

Pol Merkur Lekarski. 2010 Dec;29(174):357-60. Polish.

PMID:
21298984
10.

Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.

Fayette J, Bonnin N, Ferlay C, Lallemant B, Ramade A, Favrel V, Zrounba P, Chabaud S, Pommier P, Poupart M, Céruse P.

Anticancer Drugs. 2013 Jul;24(6):623-9. doi: 10.1097/CAD.0b013e328360b9d6.

PMID:
23542750
11.

A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.

Buiret G, Combe C, Favrel V, Pommier P, Martin L, Ecochard R, Fayette J, Tartas S, Ramade A, Céruse P.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):430-7. doi: 10.1016/j.ijrobp.2009.04.066. Epub 2009 Sep 21.

PMID:
19775831
12.

Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.

Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F, Fila G.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7.

PMID:
15145166
13.

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G.

Eur J Cancer. 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.

PMID:
22981499
14.

Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.

Yossi S, Linot B, Peyraga G, Breheret R, Laccourreye L, Capitain O.

Int J Clin Oncol. 2015 Dec;20(6):1086-92. doi: 10.1007/s10147-015-0836-1. Epub 2015 May 1.

PMID:
25931315
15.
16.

Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.

Baghi M, Hambek M, May A, Radeloff A, Gstoettner W, Knecht R.

Anticancer Res. 2006 Jan-Feb;26(1B):559-63.

17.

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Hirose S, Sakuma Y, Yamamoto K.

Br J Cancer. 2004 Jan 26;90(2):348-52.

18.

Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.

Perri F, Muto P, Argenone A, Ionna F, Longo F, Fulciniti F, Sandomenico F, Daponte A, Caponigro F.

Oncology. 2013;84(4):251-4. doi: 10.1159/000347232. Epub 2013 Feb 20.

PMID:
23428719
19.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group.

N Engl J Med. 2007 Oct 25;357(17):1705-15.

20.

Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.

Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M.

Cancer. 2003 Jan 15;97(2):412-8.

Supplemental Content

Support Center